CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Treatment Goals Based on Relapse Type in Myeloma

July 27th 2016

All Myeloma Relapses Are Not the Same

July 27th 2016

Efficacy and Safety of Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Immunotherapy Rationale in Multiple Myeloma

July 27th 2016

Dr. Stephanie Goff on Low-Dose Chemotherapy with CAR T-Cells in Advanced Lymphoma

July 27th 2016

CAR T-Cell Therapy CTL019 Shows Promise in Phase II CLL Trial

July 22nd 2016

The CD19-targeting CAR T-cell therapy CTL019 induced responses in 53% of patients with relapsed/refractory chronic lymphocytic leukemia, including complete remissions in 35% of patients.

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

June 10th 2016

CAR Therapy Achieves Durable Responses in Refractory Lymphoma

June 8th 2016

Three-fourths of patients with advanced lymphoma achieved durable objective responses to treatment with chimeric antigen receptor T-cell therapy targeting CD19 even after a low-dose chemotherapy conditioning regimen.

CAR T-cells Rapidly Evolving as Cancer Therapies

March 20th 2016

Chimeric antigen receptor-modified T-cell therapies have demonstrated durable complete responses for patients with relapsed/refractory B-cell acute lymphoblastic leukemia; however, several questions remain regarding their optimal use and applicability outside of this disease.

Allogeneic CAR T-Cell Therapy Shows Promising Efficacy Without GVHD

January 29th 2016

Treatment with allogeneic antiâ€“CD19 chimeric antigen receptorâ€“modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

Dr. Komanduri on Emerging Therapies for Patients With Hematologic Malignancies

January 8th 2016

Krishna Komanduri, MD, professor of Medicine, Microbiology, and Immunology, director, Sylvester Adult Stem Cell Transplant Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses future treatments for patients with hematologic malignancies.

Emerging Therapeutic Alternatives in Acute Lymphoblastic Leukemia

December 29th 2015

CAR T-Cell Immunotherapy in Acute Lymphoblastic Leukemia

December 29th 2015

Optimizing Blinatumomab Use in Acute Lymphoblastic Leukemia

December 29th 2015

Adverse Event Profile of Blinatumomab in ALL

December 29th 2015

Using Blinatumomab in Acute Lymphoblastic Leukemia

December 29th 2015

Salvage Therapy in Acute Lymphoblastic Leukemia

December 29th 2015

MRD Monitoring in Acute Lymphoblastic Leukemia

December 29th 2015

Allogeneic Stem Cell Transplant in ALL

December 29th 2015